what role does tigit inhibition have in treating hepatocellular carcinoma?
Published 1 year ago • 181 plays • Length 3:52Download video MP4
Download video MP3
Similar videos
-
4:53
checkpoint inhibition in hepatocellular carcinoma
-
1:03
the role of tkis in the management of hepatocellular carcinoma
-
1:12
the potential role of tigit/lag-3 inhibition in urothelial carcinoma
-
1:10
the impact of immunotherapy and checkpoint inhibition in treating hcc
-
1:16
assessing treatment options for hepatocellular carcinoma
-
1:13
choosing the best treatment regimen in advanced hepatocellular carcinoma
-
6:32
combination therapies to treat hepatocellular carcinoma
-
3:48
overcoming resistance to immune checkpoint inhibitors in nsclc
-
0:42
targeting tigit for cancer immunotherapy
-
1:21
unmet needs in immunotherapy for hepatocellular carcinoma
-
3:00
challenges and unmet needs of treating patients with hepatocellular carcinoma with radiotherapy
-
55:16
targeting tigit to extend immunotherapy benefits to more cancer patients
-
2:27
advances in fgfr inhibition for hepatobiliary cancer
-
3:23
immune checkpoints: targeting tigit
-
0:32
can addition of novel icis improve pd-(l)1 blockade in nsclc?
-
1:28
phase i trial of ntx1088, a novel anti-pvr mab, in solid tumors
-
1:33
peptide vaccines with icis for fibrolamellar hepatocellular carcinoma
-
1:48
what is the tigit bioassay? jamison grailer, phd, promega, discusses tigit bioassays.
-
0:32
will atezolizumab and bevacizumab be the new soc in high-risk hcc?